15:30 – 15:40
Topics Presented By: LIM GEOK HOON, SINGAPORE
• Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: results of the prospective multicenter RISAS trial

15.40 – 15.45
Q & A

15.45 – 15.55
Topics Presented By: FAYE LIM, SINGAPORE
• Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in women =/> 65 years with early invasive breast cancer:10 year results
• A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)

15.55 – 16.00
Q & A

16.00 – 16.20
Topics Presented By: SHAHEENAH DAWOOD, UAE
• Final invasive disease-free survival analysis of monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
• Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENEOLE-B
• 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ

16.20 – 16.25
Q & A

16.25 – 16.35
Topics Presented By: TIRA TAN, SINGAPORE
• Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: results from the neoadjuvant part of ADAPT HR+/HER2- trial
• Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: a Trans-aTTom Study

apbcs.org

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM
VIRTUAL SUMMIT
8 January 2021
15.30 – 17.25 Hrs Singapore Time
16.35 – 16.40
Q & A

16.40 – 17.05
Topics Presented By:
WONG NAN SOON, SINGAPORE

- Adjuvant trial randomized ER+ patients who had a Recurrence Score < 25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy.
- Development and validation of a tool integrating the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer.
- How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status.
- Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: First efficacy results from the ADAPT HR+/HER2- trial (n=4,690)

17.05 – 17.10
Q & A

17.10 – 17.35
Topics Presented By:
JOLINE LIM, SINGAPORE

- Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
- Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
- Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane.
- Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies.

17.35 – 17.40
Q & A